Article
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Oncotarget - 20 Oct 2015
Marabese Mirko, Ganzinelli Monica, Garassino Marina C, Shepherd Frances A, Piva Sheila, Caiola Elisa, Macerelli Marianna, Bettini Anna, Lauricella Calogero, Floriani Irene, Farina Gabriella, Longo Flavia, Bonomi Lucia, Fabbri M Agnese, Veronese Silvio, Marsoni Silvia, Broggini Massimo, Rulli Eliana
Abstract excerpt
UNLABELLED: KRAS mutations seem to indicate a poor outcome in Non-Small-Cell Lung Cancer (NSCLC) but such evidence is still debated. The aim of this planned ancillary study within the TAILOR trial was to assess the prognostic value of KRAS mutations in advanced NSCLC patients treated with platinum-based first-line chemotherapy. Patients (N = 540), enrolled in the study in 52 Italian hospitals, were centrally...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.